Homepage>Company>Media>Pharma News>2018>Pfizer Inc. announced that the FDA approved XELJANZ® (tofacitinib) for the treatment of patients with moderately to severely active ulcerative colitis
Pfizer Inc. announced that the FDA approved XELJANZ® (tofacitinib) for the treatment of patients with moderately to severely active ulcerative colitis